An Anticopper Antiangiogenic Approach for Advanced Cancer in Spontaneously Occurring Tumors Using Tetrathiomolybdate: A Pilot Study in a Canine Animal Model

Michael S Kent, Bruce R. Madewell, Gillian Dank, Robert Dick, Sofia D. Merajver, George J. Brewer

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

In this pilot study, 13 dogs of various breeds and ages with a variety of advanced tumors were treated with the antiangiogenic copper complexing drug tetrathiomolybdate. Dose escalations were performed to determine the safe and effective dose in dogs. The study was designed to last for a 6-month period for each dog entered. Dogs were examined weekly for the first 3 months and then every other week for the next 3 months. Complete blood count, serum biochemistry panel, and measurement of serum ceruloplasmin (Cp) content were conducted at each visit to monitor response to drug administration. Serum Cp was used as a surrogate marker of copper status. The owner reported toxicity at each visit. The dog was examined for physical abnormalities. Tumor measurements were completed every 2 weeks using direct measurements of the tumor with calipers in three planes or by direct measurements of the tumor using radiographic or ultrasonographic images in two planes. Tumor response was evaluated only after dogs achieved a 4-week reduction in their serum Cp content. Tumor responses were defined as either disease stabilization or reduction in tumor volume. Nine dogs achieved Cp reduction. Of those dogs, five had no response to treatment, whereas four dogs had tumor responses after Cp reduction, characterized as either disease stabilization or reduction in tumor volume, for the remainder of the study period. There was only mild self-limiting toxicity with use of the drug.

Original languageEnglish (US)
Pages (from-to)9-20
Number of pages12
JournalJournal of Trace Elements in Experimental Medicine
Volume17
Issue number1
DOIs
StatePublished - 2004

Fingerprint

Canidae
Tumors
Animals
Animal Models
Dogs
Ceruloplasmin
Neoplasms
Tumor Burden
Serum
Toxicity
Copper
Stabilization
Pharmaceutical Preparations
tetrathiomolybdate
Biochemistry
Blood Cell Count
Blood
Biomarkers

Keywords

  • Angiogenesis
  • Copper
  • Dog
  • Neoplasia

ASJC Scopus subject areas

  • Biochemistry

Cite this

An Anticopper Antiangiogenic Approach for Advanced Cancer in Spontaneously Occurring Tumors Using Tetrathiomolybdate : A Pilot Study in a Canine Animal Model. / Kent, Michael S; Madewell, Bruce R.; Dank, Gillian; Dick, Robert; Merajver, Sofia D.; Brewer, George J.

In: Journal of Trace Elements in Experimental Medicine, Vol. 17, No. 1, 2004, p. 9-20.

Research output: Contribution to journalArticle

@article{562d53a5e4c8424f84ae96532242df8e,
title = "An Anticopper Antiangiogenic Approach for Advanced Cancer in Spontaneously Occurring Tumors Using Tetrathiomolybdate: A Pilot Study in a Canine Animal Model",
abstract = "In this pilot study, 13 dogs of various breeds and ages with a variety of advanced tumors were treated with the antiangiogenic copper complexing drug tetrathiomolybdate. Dose escalations were performed to determine the safe and effective dose in dogs. The study was designed to last for a 6-month period for each dog entered. Dogs were examined weekly for the first 3 months and then every other week for the next 3 months. Complete blood count, serum biochemistry panel, and measurement of serum ceruloplasmin (Cp) content were conducted at each visit to monitor response to drug administration. Serum Cp was used as a surrogate marker of copper status. The owner reported toxicity at each visit. The dog was examined for physical abnormalities. Tumor measurements were completed every 2 weeks using direct measurements of the tumor with calipers in three planes or by direct measurements of the tumor using radiographic or ultrasonographic images in two planes. Tumor response was evaluated only after dogs achieved a 4-week reduction in their serum Cp content. Tumor responses were defined as either disease stabilization or reduction in tumor volume. Nine dogs achieved Cp reduction. Of those dogs, five had no response to treatment, whereas four dogs had tumor responses after Cp reduction, characterized as either disease stabilization or reduction in tumor volume, for the remainder of the study period. There was only mild self-limiting toxicity with use of the drug.",
keywords = "Angiogenesis, Copper, Dog, Neoplasia",
author = "Kent, {Michael S} and Madewell, {Bruce R.} and Gillian Dank and Robert Dick and Merajver, {Sofia D.} and Brewer, {George J.}",
year = "2004",
doi = "10.1002/jtra.10033",
language = "English (US)",
volume = "17",
pages = "9--20",
journal = "Journal of Trace Elements in Experimental Medicine",
issn = "0896-548X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - An Anticopper Antiangiogenic Approach for Advanced Cancer in Spontaneously Occurring Tumors Using Tetrathiomolybdate

T2 - A Pilot Study in a Canine Animal Model

AU - Kent, Michael S

AU - Madewell, Bruce R.

AU - Dank, Gillian

AU - Dick, Robert

AU - Merajver, Sofia D.

AU - Brewer, George J.

PY - 2004

Y1 - 2004

N2 - In this pilot study, 13 dogs of various breeds and ages with a variety of advanced tumors were treated with the antiangiogenic copper complexing drug tetrathiomolybdate. Dose escalations were performed to determine the safe and effective dose in dogs. The study was designed to last for a 6-month period for each dog entered. Dogs were examined weekly for the first 3 months and then every other week for the next 3 months. Complete blood count, serum biochemistry panel, and measurement of serum ceruloplasmin (Cp) content were conducted at each visit to monitor response to drug administration. Serum Cp was used as a surrogate marker of copper status. The owner reported toxicity at each visit. The dog was examined for physical abnormalities. Tumor measurements were completed every 2 weeks using direct measurements of the tumor with calipers in three planes or by direct measurements of the tumor using radiographic or ultrasonographic images in two planes. Tumor response was evaluated only after dogs achieved a 4-week reduction in their serum Cp content. Tumor responses were defined as either disease stabilization or reduction in tumor volume. Nine dogs achieved Cp reduction. Of those dogs, five had no response to treatment, whereas four dogs had tumor responses after Cp reduction, characterized as either disease stabilization or reduction in tumor volume, for the remainder of the study period. There was only mild self-limiting toxicity with use of the drug.

AB - In this pilot study, 13 dogs of various breeds and ages with a variety of advanced tumors were treated with the antiangiogenic copper complexing drug tetrathiomolybdate. Dose escalations were performed to determine the safe and effective dose in dogs. The study was designed to last for a 6-month period for each dog entered. Dogs were examined weekly for the first 3 months and then every other week for the next 3 months. Complete blood count, serum biochemistry panel, and measurement of serum ceruloplasmin (Cp) content were conducted at each visit to monitor response to drug administration. Serum Cp was used as a surrogate marker of copper status. The owner reported toxicity at each visit. The dog was examined for physical abnormalities. Tumor measurements were completed every 2 weeks using direct measurements of the tumor with calipers in three planes or by direct measurements of the tumor using radiographic or ultrasonographic images in two planes. Tumor response was evaluated only after dogs achieved a 4-week reduction in their serum Cp content. Tumor responses were defined as either disease stabilization or reduction in tumor volume. Nine dogs achieved Cp reduction. Of those dogs, five had no response to treatment, whereas four dogs had tumor responses after Cp reduction, characterized as either disease stabilization or reduction in tumor volume, for the remainder of the study period. There was only mild self-limiting toxicity with use of the drug.

KW - Angiogenesis

KW - Copper

KW - Dog

KW - Neoplasia

UR - http://www.scopus.com/inward/record.url?scp=1642499579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642499579&partnerID=8YFLogxK

U2 - 10.1002/jtra.10033

DO - 10.1002/jtra.10033

M3 - Article

AN - SCOPUS:1642499579

VL - 17

SP - 9

EP - 20

JO - Journal of Trace Elements in Experimental Medicine

JF - Journal of Trace Elements in Experimental Medicine

SN - 0896-548X

IS - 1

ER -